Clinical trials
Prostate Cancer (Adenocarcinoma) clinical trials
Below are recruiting prostate cancer (adenocarcinoma) clinical trials, each written for real people, not researchers. We’re tracking 547 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06925737RecruitingPhase 3
Study of I-DXd for metastatic prostate cancer
This study tests a new drug called Ifinatamab Deruxtecan (I-DXd) for people with metastatic prostate cancer that has stopped responding to hormone therapy. It may help by targeting and destroying cancer cells in a different way.
Phoenix, ArizonaAges 18 years+ - NCT07824349RecruitingPhase 1
JUR-003 for metastatic prostate cancer
This trial tests an experimental drug called JUR-003 in people with prostate cancer that has spread to other parts of the body. It aims to see if the drug can shrink tumors or slow the cancer's growth.
Grand Rapids, MichiganAges 18 years+ - NCT03294889RecruitingPhase 1/Phase 2
Single-dose SBRT for early prostate cancer
This trial tests a very short, one-time form of radiation (SBRT) to treat prostate cancer. It aims to see whether treating the prostate in one shot is safe and effective for carefully selected patients.
GenevaAges 18–85 - NCT03541928RecruitingPhase 2
Gene therapy with standard treatment for high-risk prostate cancer
This trial combines gene therapy with hormone therapy, radiation, and possibly surgery to treat high-risk prostate cancer. It aims to improve outcomes by adding gene therapy to standard treatments and will require additional biopsies.
Houston, TexasAges 18 years+ - NCT03787056Recruiting
Blood test marker study in many cancer types
This study measures a blood marker called progastrin (at diagnosis and during treatment) to see how well it predicts response or outcomes. It may help doctors choose or monitor treatment more precisely for several cancer types.
BronAges 18 years+ - NCT04700332RecruitingPhase 2
Test of PyL PET/CT for high-risk or returning prostate cancer
This Phase 2 study checks how well a scan called PyL PET/CT can help find prostate cancer that is high-risk or has come back by blood test. The goal is to improve how doctors detect spread and guide the next treatment steps.
Irvine, CaliforniaAges 18 years+ - NCT04146077Recruiting
Active monitoring for low-risk prostate cancer
This study tests whether watching low-risk prostate cancer closely (instead of treating right away) is safe. It may help some people avoid early treatments and their side effects while still keeping a close eye on the cancer.
MoscowAges 50–75 - NCT04231006Recruiting
High-dose salvage radiation for prostate cancer that came back locally
This trial studies high-dose radiation (HDR) given after prostate cancer returns only in the prostate/seminal vesicles. It may help by trying to control the cancer when it has not spread elsewhere, using targeted treatment based on MRI and biopsy proof.
Aarhus, Region MidtAges 18 years+ - NCT05022914Recruiting
PSMA PET/CT scan for PSA relapse after prostate surgery
This trial looks at using a PSMA PET/CT scan to better re-check cancer activity in men whose PSA has started rising after prostate removal. If you qualify, the scan may help doctors choose the next best treatment step.
FlorenceAges 18 years+ - NCT04894188Recruiting
Hormone plus radiation before prostate surgery for high-risk cancer
This trial studies giving hormone treatment and radiation before prostate surgery to treat high-risk, locally advanced prostate cancer. It aims to improve cancer control by shrinking or controlling the tumor before removing it.
Douliu City/Huwei Township, Yunlin CountyAges 20–75 - NCT03753243RecruitingPhase 2
Pembrolizumab and hormone blocker before prostate surgery
This Phase 2 trial studies whether pembrolizumab plus a hormone “androgen axis” blocker taken before prostate surgery can improve outcomes for people with high-risk, non-metastatic prostate cancer. It’s designed for patients who are planning prostate removal with an extended lymph node dissection.
Portland, OregonAges 18 years+ - NCT04595019Recruiting
Shorter faster radiation with hormone treatment for prostate cancer
This trial studies a more sped-up radiation schedule for men with certain local prostate cancers, given together with hormone therapy. It aims to keep cancer control while possibly reducing treatment time and making care easier.
Sutton, SurreyAges 18 years+ - NCT03789253Recruiting
Tracking genetic changes as low-risk prostate cancer becomes riskier
This study looks for genes and biological pathways that may explain why some men’s prostate cancer grows from low risk to higher risk. You may be followed using planned prostate biopsies after an initial low-risk diagnosis managed with active surveillance.
TaipeiAges 40–100 - NCT05557604RecruitingPhase 2
Tested a targeted prostate cancer radiation plan for higher-risk patients
This Phase 2 trial studies whether a specific radiation approach (including detailed targeting and tracking) can work better for men with intermediate-risk to high-risk prostate cancer. You may be eligible if your scans show no spread beyond the prostate area and you can safely complete the required imaging and treatments.
Rome, LazioAges 18–90 - NCT05597852Recruiting
Rectal gel spacer to help repeat prostate radiation
This trial studies whether placing a soft gel spacer near the rectum can make “salvage” prostate radiation safer and more tolerable when prostate cancer comes back locally. It may help reduce side effects by creating extra space between the rectum and the radiation area.
Toronto, OntarioAges 18 years+ - NCT05753566RecruitingPhase 2
Rezvilutamide for prostate cancer PSA rise after prostate surgery
This Phase 2 study tests rezvilutamide in men whose prostate-specific antigen (PSA) starts rising again after the prostate has been removed. It aims to see whether this treatment can help prevent or slow cancer spread after surgery, especially in men without signs of spread on scans.
Nanjing, JiangsuAges 40 years+ - NCT05054296RecruitingPhase 2
Exercise and Fitbit monitoring to lower heart risk in prostate cancer
This Phase 2 study tests whether a structured exercise and lifestyle program, tracked with a Fitbit, can reduce cardiovascular (heart) risk in men with prostate cancer on hormone therapy. It also checks whether this is safe and feasible while monitoring symptoms and fitness changes.
Houston, TexasAges 18 years+ - NCT04861415Recruiting
Testing a shorter radiation plan versus standard prostate radiation
This study compares two ways of giving radiation to the prostate, including a “boost” using a special internal radiation treatment. It’s meant to see which radiation schedule works better and is safer for certain prostate cancer patients.
Toronto, OntarioAges 18 years+ - NCT05019846RecruitingPhase 3
Radiation alone versus radiation plus hormone therapy for prostate cancer
This Phase 3 trial compares two treatment approaches: stereotactic radiation therapy by itself versus the same radiation plus hormone therapy (ADT). It aims to see which plan works better for men with higher-risk prostate cancer without spread to lymph nodes or distant sites.
Brescia, BSAges 18–80 - NCT04654338RecruitingPhase 2/Phase 3
Two types of targeted radiation for favorable prostate cancer
This trial tests whether two “ablative” (high-dose, focused) radiation treatments can work well for men with favorable-risk prostate cancer. It looks at whether the treatments are practical and safe, especially for urinary side effects.
Toronto, OntarioAges Any age - NCT05851365RecruitingEarly Phase 1
MRI scan to measure prostate acidity before surgery
This study tests a new MRI technique that measures acidity in prostate tumors. It may help doctors better understand the cancer before surgery, potentially guiding treatment decisions.
San Francisco, CaliforniaAges 18 years+ - NCT07856017Recruiting
Smarter prostate biopsy using imaging and metabolic data
This study tests a new biopsy system that uses MRI images and metabolic information to guide doctors to the most suspicious areas of the prostate during the biopsy. This could make the biopsy more accurate and help diagnose prostate cancer better.
ShanghaiAges 55 years+ - NCT06219746Recruiting
New imaging scan for high-risk prostate cancer staging
This trial tests a special type of scan (99mTc-MIP-1404 SPECT/CT) to see how well it can detect the spread of high-risk prostate cancer. It may help doctors better understand the stage of the disease before deciding on treatment.
Turku, Southwest FinlandAges 18 years+ - NCT07860047RecruitingPhase 2
Peptide vaccine with antibody therapy for prostate cancer
This trial tests a combination of a personalized peptide vaccine and an antibody therapy for men with prostate cancer that has returned after initial treatment. The goal is to see if this approach can control the cancer without needing stronger hormone therapy.
Heidelberg, Baden-WurttembergAges 18–80
Hear when a new Prostate Cancer (Adenocarcinoma) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Prostate Cancer (Adenocarcinoma) trials by city
Studies with a site in or near these metro areas.
Prostate Cancer (Adenocarcinoma) trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for prostate cancer (adenocarcinoma)?
- Yes. Clin2 currently lists 547 recruiting prostate cancer (adenocarcinoma) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a prostate cancer (adenocarcinoma) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a prostate cancer (adenocarcinoma) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.